Adults with ADHD have never had a real rulebook. Pediatric ADHD has had formal diagnostic and treatment guidelines for decades. Adults got extrapolation — a clinician taking the kid version, subtracting a few assumptions about hyperactivity, and hoping it held up in a 45-year-old with a job and a mortgage. On August 28, 2026, APSARD announced that its US Adult ADHD Guidelines have entered Stage 3, the final review phase before publication. If you’ve ever sat across from a doctor who seemed to be making it up as they went, this is the reason why — and it’s finally about to change.

That’s not an exaggeration or a dig at individual clinicians. There has never been a formal, published US clinical practice guideline for diagnosing or treating ADHD in adults. Not one. Everything your prescriber has done — which rating scale to use, how long to trial a stimulant before switching, whether therapy or medication comes first — has been built on pediatric frameworks, individual training, and professional judgment. That’s exactly why two people with identical symptoms can walk into two different offices and get two completely different diagnostic experiences.

TL;DR: What’s Actually Happening

What happened	APSARD announced Aug. 28, 2026 that its US Adult ADHD Guidelines reached Stage 3 — final review before publication
Why it matters	This will be the first-ever formal US clinical practice guideline for adult ADHD diagnosis and treatment
Built by	3 subcommittees, 2 years of work: screening/diagnosis, medication/medical treatments, psychosocial/nonmedical interventions
Who’s leading it	APSARD President Brooke Molina, PhD, who called Stage 3 the final step before publication
When it publishes	Fall 2026
Also covering it	Psychiatric Times, Medscape, ADDitude, CHADD
Our take	This won’t fix your specific doctor by fall. But it gives you something to point to the next time one doubts you

Why Has Adult ADHD Diagnosis Been Such a Mess?

Because there was nothing to standardize against. Pediatric ADHD guidelines exist through organizations like the American Academy of Pediatrics, and have for years. Adult ADHD had no equivalent — just individual clinician training, borrowed pediatric criteria never validated for adult presentation, and whatever rating scale a given practice happened to adopt.

We’ve written before about what that gap actually costs people. The surge in adult ADHD diagnoses — a roughly 20-fold increase in UK men 18-29 between 2000 and 2018 — is landing on adults with zero infrastructure built for them: no childhood 504 plan, no established diagnostic pathway, nothing but a prescriber winging it. Same story with women diagnosed in their 30s and 40s, whose inattentive presentation doesn’t match the hyperactive-boy template most clinicians were trained to spot. Inconsistent guidelines don’t just mean inconsistent paperwork. They mean some people get taken seriously and some don’t, based on which office they happened to walk into.

Compare that to K-12, where at least the legal framework is settled — we’ve covered how 504 plans and IEPs work because that system, whatever its flaws, has actual rules written into federal law. Adults asking their doctor for a diagnosis have had no equivalent floor to stand on. That’s the gap APSARD is trying to close.

Ask around and you’ll hear the same handful of stories. One doctor wants six months of symptom tracking before they’ll consider a diagnosis. Another writes a prescription after a fifteen-minute intake. A third insists you must have shown symptoms before age 12 and won’t budge on it, even when the picture is messier than that in practice. None of these clinicians are necessarily bad at their jobs. They’re each filling a gap with their own best judgment, because there was never a shared standard telling them what the floor should be.

What Is APSARD, and What Does “Stage 3” Actually Mean?

APSARD (the American Professional Society of ADHD and Related Disorders) is the professional body that’s spent the past several years building the first formal US clinical practice guidelines for adult ADHD. Stage 3 is the final review phase before publication — the draft guidelines go out to a broad range of clinical disciplines and people with lived ADHD experience for feedback, which then gets folded into the manuscript before it’s submitted for publication.

In plain terms: the guidelines are written. What’s happening now is the last round of stress-testing before they become official.

What Will the Guidelines Actually Cover?

The framework was built over two years by three separate subcommittees, each responsible for one piece of adult ADHD care:

1. Screening and diagnosis — standardizing how adult ADHD gets identified in the first place, instead of leaving it to whichever rating scale a given clinic happens to use.
2. Medication and other medical treatments — a formal framework for stimulant and non-stimulant prescribing in adults, not a pediatric dosing chart adjusted by guesswork.
3. Psychosocial and other nonmedical interventions — where therapy, coaching, and behavioral approaches fit for adults, and when they should come before or alongside medication.

That structure matters. It means the guidelines aren’t just “here’s which pill to try first” — they’re supposed to give clinicians a diagnostic pathway and a treatment framework that covers people who don’t want medication at all, which is worth noting for anyone building a medication-free system by choice or necessity.

Why Did This Take Two Years?

Because nobody had done it before, and doing it badly would have been worse than not doing it at all. According to CHADD, the guidelines draw on research from the Adult ADHD Quality Measures Initiative — a five-year effort developing and testing quality metrics for adult ADHD care before the guideline-writing subcommittees even started their work. CHADD has partnered with APSARD through what it calls the Adult ADHD Coalition, which includes representatives from the American Psychiatric Association, the American Academy of Neurology, the American Psychological Association, and the National Alliance on Mental Illness, among others — building toward an educational toolkit meant to get these guidelines in front of the clinicians actually seeing patients, with CHADD’s distribution timeline targeting 2027, a year after the guidelines themselves publish.

That gap between “guidelines exist” and “your doctor has actually internalized them” is real, and worth sitting with. Publication in fall 2026 doesn’t mean every prescriber in the country changes their approach in October.

What Changes for You Once This Publishes

Not everything, and not immediately. But a few things shift in a way that’s worth tracking:

You’ll have something to point to. If a doctor waves off an adult ADHD concern or applies criteria that sound more like the pediatric checklist than anything adult-specific, “there’s now a formal APSARD guideline for this” is a very different conversation than “I read about this online.”

Insurance friction may get some cover. A chunk of the coverage denials and prior-authorization fights people describe come down to inconsistent diagnostic documentation across providers. A shared national standard doesn’t eliminate insurance friction — nothing does that — but it gives clinicians a consistent framework to document against.

The “is this just pediatric ADHD with extra steps” question gets an actual answer. For the first time, adult-specific screening criteria, medication guidance, and nonmedical treatment guidance exist as one coordinated document instead of three separately borrowed sources.

This sits in the same category as the first-ever expert consensus on deprescribing ADHD stimulants published earlier in 2026 — another instance of a field finally writing down, formally, what had only existed as scattered individual practice. Adult ADHD care keeps getting its missing rulebooks filled in, one piece at a time.

The Honest Caveat

Guidelines are not enforcement. Nothing about Stage 3 completing in fall 2026 requires any individual clinician to read the document, let alone change how they practice. CHADD’s own toolkit rollout isn’t targeted until 2027, and that’s specifically the effort meant to get frontline providers up to speed. A guideline sitting in a journal doesn’t help you in an appointment next month.

What it does is give you something solid to stand on that didn’t exist before. A skeptical doctor operating on outdated assumptions about adult ADHD is now going to be increasingly out of step with a published national standard, not just with “what some people say online.” That’s a slower fix than most of us want. It’s still a real one.

Our Take

This is the kind of news that undersells itself in a headline. “Guidelines entered final review” sounds bureaucratic. What it actually means is that the single biggest structural reason adult ADHD diagnosis has felt like a coin flip — no shared standard, ever, in this country — is finally getting fixed. Not fixed by fall. But fixed on a real timeline, by a real coalition, after real subcommittee work, for the first time since adult ADHD started getting taken seriously as its own condition rather than a leftover from childhood.

If you’re currently navigating a diagnosis, a skeptical provider, or an insurance denial, this guideline won’t land in time to help you this month. But it’s worth remembering the next time someone tells you adult ADHD “isn’t really a thing” or that your experience doesn’t match what they were taught. Soon, there will be an actual document saying otherwise.

---

Not medical advice. Guideline publication timelines can shift, and clinical adoption after publication typically takes longer than the guidelines themselves.